18F-16α-17β-Fluoroestradiol Binding Specificity in Estrogen Receptor-Positive Breast Cancer

被引:18
|
作者
Salem, Kelley [1 ]
Kumar, Manoj [1 ]
Powers, Ginny L. [1 ,5 ]
Jeffery, Justin J. [2 ]
Yan, Yongjun [1 ,3 ]
Mahajan, Aparna M. [4 ]
Fowler, Amy M. [1 ,2 ,3 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, 600 Highland Ave, Madison, WI 53792 USA
[2] Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, 600 Highland Ave, Madison, WI 53792 USA
[3] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Phys, 600 Highland Ave, Madison, WI 53792 USA
[4] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, 600 Highland Ave, Madison, WI 53792 USA
[5] Kendrick Labs, Madison, WI USA
关键词
POSITRON-EMISSION-TOMOGRAPHY; PROTEASOME-MEDIATED PROTEOLYSIS; SMALL-ANIMAL PET; IN-VIVO; TARGET TISSUES; ESR1; MUTATIONS; F-18-FLUOROESTRADIOL; THERAPY; RESPONSIVENESS; FEASIBILITY;
D O I
10.1148/radiol.2017162956
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine the binding specificity of F-18-16 alpha-17 beta-fluoroestradiol (FES) in estrogen receptor (ER) alpha-positive breast cancer cells and tumor xenografts. Materials and Methods: Protocols were approved by the office of biologic safety and institutional animal care and use committee. By using ER-negative MDA-MB-231 breast cancer cells, clonal lines were created that expressed either wild-type (WT; 231 WT ER) or G521R mutant ER alpha (231 G521R ER), which is defective in estradiol binding. ERa protein levels, subcellular localization, and transcriptional function were confirmed. FES binding was measured by using an in vitro cell uptake assay. In vivo FES uptake was measured in tumor xenografts by using small-animal positron emission tomographic/computed tomographic imaging of 24 mice (17 WT ER tumors, nine mutant G521R ER tumors, eight MDA-MB-231 tumors, and four MCF-7 ER-positive tumors). Statistical significance was determined by using Mann-Whitney (Wilcoxon rank sum) test. Results: ERa transcriptional function was abolished in the mutated 231 G521R ER cells despite appropriate receptor protein expression and nuclear localization. In vitro FES binding in the 231 G521R ER cells was reduced to that observed in the parental cells. Similarly, there was no significant FES uptake in the 231 G521R ER xenografts (percent injected dose [ ID] per gram, 0.49 +/- 0.042), which was similar to the negative control MDA-MB-231 xenografts (percent ID per gram, 0.42 +/- 0.051; P =.20) and nonspecific muscle uptake (percent ID per gram, 0.41 +/- 0.0095; P =.06). Conclusion: This study showed that FES retention in ER-positive breast cancer is strictly dependent on an intact receptor ligand-binding pocket and that FES binds to ERa with high specificity. These results support the utility of FES imaging for assessing tumor heterogeneity by localizing immunohistochemically ER-positive metastases that lack receptor-binding functionality. (C) RSNA, 2017
引用
收藏
页码:868 / 876
页数:9
相关论文
共 50 条
  • [31] Estrogen receptor β- an independent prognostic marker in estrogen receptor α and progesterone receptor-positive breast cancer?
    Maehle, Bjorn O.
    Collett, Karin
    Tretli, Steinar
    Akslen, Lars A.
    Grotmol, Tom
    APMIS, 2009, 117 (09) : 644 - 650
  • [32] MicroRNAs in estrogen receptor-positive and -negative breast cancer cells
    Miyamoto, Kazuaki
    Miyamoto, Haruko
    CANCER RESEARCH, 2009, 69
  • [33] The impact of CBP expression in estrogen receptor-positive breast cancer
    Wafaa S. Ramadan
    Iman M. Talaat
    Mahmood Y. Hachim
    Annette Lischka
    Timo Gemoll
    Raafat El-Awady
    Clinical Epigenetics, 2021, 13
  • [34] A novel oncogenic enhancer of estrogen receptor-positive breast cancer
    Bao, Chunjie
    Duan, Jialun
    Xie, Ying
    Liu, Yixuan
    Li, Peishan
    Li, Jianwei
    Zhao, Huihui
    Guo, Haitao
    Men, Yanchen
    Ren, Yuxin
    Xu, Jiarui
    Wang, Guiling
    Lu, Wanliang
    MOLECULAR THERAPY NUCLEIC ACIDS, 2022, 29 : 836 - 851
  • [35] Update on estrogen receptor-positive breast cancer risk reduction
    Vogel V.G.
    Current Breast Cancer Reports, 2011, 3 (3) : 156 - 164
  • [36] The impact of CBP expression in estrogen receptor-positive breast cancer
    Ramadan, Wafaa S.
    Talaat, Iman M.
    Hachim, Mahmood Y.
    Lischka, Annette
    Gemoll, Timo
    El-Awady, Raafat
    CLINICAL EPIGENETICS, 2021, 13 (01)
  • [37] Late Recurrences After Estrogen Receptor-Positive Breast Cancer
    Narod, Steven A.
    Giannakeas, Vasily
    Sopik, Victoria
    JAMA ONCOLOGY, 2020, 6 (02) : 301 - +
  • [38] The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer
    Kwa, Maryann
    Plottel, Claudia S.
    Blaser, Martin J.
    Adams, Sylvia
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (08):
  • [39] Leptin as a Potential Target for Estrogen Receptor-Positive Breast Cancer
    Yom, Cha Kyong
    Lee, Kyung-Min
    Han, Wonshik
    Kim, Sung-Won
    Kim, Hee Sung
    Moon, Byung In
    Jeong, Ku-Young
    Im, Seock-Ah
    Noh, Dong-Young
    JOURNAL OF BREAST CANCER, 2013, 16 (02) : 138 - 145
  • [40] Evaluation of estrogen receptor (ER) with 18F-fluoroestradiol in biopsy-proven ER positive breast cancer patients resistant to hormonal therapy
    Ohnishi, Akihito
    Senda, Michio
    Sasaki, Masahiro
    Akamatsu, Go
    Nishida, Hiroyuki
    Aita, Kazuki
    Kikawa, Yuichiro
    Kato, Hironori
    Masai, Yoshikazu
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55